Publications by authors named "Ruoxin Du"

Claim this Profile
T
Targeting PDPN CAFs enhances treatment efficacy of trastuzumab by reversing immunosuppressive microenvironment in HER2-positive breast cancer.
Shuangpeng Pu, Tianguang Liu, Lisiyao You, Guodong Li, Ruoxin Du

Int Immunopharmacol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved Efficacy of Triple-Negative Breast Cancer Immunotherapy via Hydrogel-Based Co-Delivery of CAR-T Cells and Mitophagy Agonist.
Guodong Li, Ruoxin Du, Donghui Wang, Xiangmei Zhang, Lizhuo Wang

Adv Sci (Weinh)· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NK cell immunopotentiators-loaded nanoliposomes enhance ADCC effect for targeted therapy against HER2-positive breast cancer.
Ruoxin Du, Changqing Cao, Dong Fan, Guodong Li, Shuangpeng Pu

Cell Commun Signal· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of METTL14 overcomes CDK4/6 inhibitor resistance driven by METTL14-m6A-E2F1-axis in ERα-positive breast cancer.
Chenlin Liu, Dong Fan, Jiahui Sun, Guodong Li, Ruoxin Du, Mingrui Du

J Nanobiotechnology· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD63 cancer-associated fibroblasts confer CDK4/6 inhibitor resistance to breast cancer cells by exosomal miR-20.
Jiahui Sun, Ruoxin Du, Xiaoju Li, Chenlin Liu, Donghui Wang

Cancer Lett· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Engineering CAR-NK cell derived exosome disguised nano-bombs for enhanced HER2 positive breast cancer brain metastasis therapy.
Bolong Tao, Ruoxin Du, Xiangmei Zhang, Bo Jia, Yuan Gao

J Control Release· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PDPN positive CAFs contribute to HER2 positive breast cancer resistance to trastuzumab by inhibiting antibody-dependent NK cell-mediated cytotoxicity.
Ruoxin Du, Xiangmei Zhang, Xiyan Lu, Xiangmin Ma, Xinyan Guo

Drug Resist Updat· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epitranscriptomic editing of the RNA N6-methyladenosine modification by dCasRx conjugated methyltransferase and demethylase.
Zhen Xia, Min Tang, Jiayan Ma, Hongyan Zhang, Ryan C Gimple, Ruoxin Du

Nucleic Acids Res· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis